BAXTER INTERNATIONAL INC.;BAXTER HEALTHCARE SA;BOARD OF REGENTS, THE UNIVERSITY OF TEXAS
发明人:
BRETT GIROIR,MONTE WILLIS,VIDAL DE LA CRUZ,THAIS SIELECKI
申请号：
PT04782427
公开号：
PT1658037T
申请日:
2004.08.30
申请国别(地区):
PT
年份:
2016
代理人:
摘要：
An embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody； and at least on pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-CD74 antibody； and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-TNFR antibody； a therapeutically effective amount of at least one anti-MIF antibody； and at least one pharmaceutically acceptable carrier. Other embodiments of the present invention relate to methods of treating or preventing cardiac dysfunction, cardiodepression, burn injury-associated cardiac dysfunction, improving cardiac function in a subject following acute myocardial infarction and identifying an MIF inhibitor.
